Search the Newsreel

NXTC|NextCure Inc|Price:5.200|Chg%:+0.960

This article provides a comprehensive stock analysis of NextCure Inc (NXTC) by TradingKey, highlighting its "Smarter Investment Decisions" score. It details the company's fundamentals, growth potential, valuation, institutional ownership, and analyst ratings, alongside its strong market performance and clinical-stage biopharmaceutical focus. The analysis also …

NextCure Inc (NXTC) Balance Sheet

This article provides comprehensive quarterly and annual balance sheet data for NextCure Inc (NXTC), covering assets, liabilities, and shareholders' equity from FY2019Q1 to FY2026Q1. It allows users to assess the company's financial health, liquidity, leverage, and return on equity through various metrics. The content …

NextCure Inc (NXTC) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of NextCure Inc's (NXTC) dividend and stock split history. It states that no dividends have been distributed by the company over the past five years. The article also lists a stock split event for July 10, 2025, which is …

NextCure, Inc. Revenue Breakdown – MUN:2US0

This article provides financial information for NextCure, Inc. (MUN:2US0) on the TradingView platform. It details access to financials, market data, and various tools offered by TradingView for analyzing the company's performance. The article also lists several sections related to community, education, and business solutions …

What's Going On With Exco Technologies Limited Stock Friday?

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--VEEE, NXTC, TCBK, and FHB

Monteverde & Associates PC, a class action firm, has launched legal inquiries into the mergers involving Twin Vee PowerCats Co. (VEEE) with USFM Corporation, NextCure, Inc. (NXTC) with Avere Therapeutics, Inc., and TriCo Bancshares (TCBK) with First Hawaiian, Inc. (FHB). The firm is investigating …

NextCure Inc. (NXTC) Q1 2026 Earnings: EPS Beats Estimates, Stock Declines on Pre-Revenue Status - ROIC Trend Report

Shareholder Alert: Ademi LLP investigates whether NextCure, Inc. is obtaining a Fair Price for Public Shareholders

Ademi LLP is investigating NextCure (NASDAQ: NXTC) regarding potential breaches of fiduciary duty related to its transaction with Avere Therapeutics. The investigation focuses on whether the merger terms, which result in NextCure stockholders holding only 1.21% of the combined company, ensure a fair price …

NextCure announces reverse merger with privately held Avere

NextCure (NASDAQ: NXTC) announced a reverse merger with privately held Avere. This strategic transaction aims to combine NextCure's public listing with Avere's private operations to create a new entity. The merger details are expected to be elaborated upon by the companies.

NextCure (NASDAQ: NXTC) details Avere merger structure and S-4 plan

NextCure (NASDAQ: NXTC) has detailed a proposed two-step merger with Avere Therapeutics, Inc., as per an Agreement and Plan of Merger and Reorganization dated July 14, 2026. The initial step involves Neptune Merger Sub Corp. merging into Avere, making Avere a wholly-owned subsidiary of …

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of NextCure, Inc. (NASDAQ: NXTC)

Monteverde & Associates PC has launched an investigation into NextCure, Inc. (NASDAQ: NXTC) following its proposed merger with Avere Therapeutics, Inc. NextCure shareholders are expected to own approximately 1.21% of the combined company, and the firm is evaluating the fairness of this deal for …

Beltsville's NextCure merging with San Francisco startup

NextCure Inc., a Beltsville-based biotechnology company focused on cancer treatments, is merging with San Francisco startup Avere Therapeutics in an all-stock deal. NextCure had not yet brought a product to market. The acquisition includes United Therapeutics buying a biotech firm for $140M as well …

NextCure (NXTC) Slides As Avere Merger Triggers Legal Scrutiny

NextCure (NXTC) stock has slid by over 12% following news of its merger with Avere Therapeutics, triggering legal scrutiny from multiple investor-rights firms. Shareholders of NextCure are set to own only about 1.21% of the combined company, with a contingent value right for 90% …

NextCure to Merge With Avere in Stock Deal; $320 Million PIPE to Fund Combined Company

NextCure has signed a definitive merger agreement with Avere Therapeutics in a stock-for-stock transaction, which will result in Avere holders owning approximately 98% of the combined company, to be renamed Avere Therapeutics. To finance the merger, Avere secured a $320 million private placement from …

NextCure Announces Transformative All-Stock Merger With Avere

NextCure (NXTC) announced an all-stock merger with Avere Therapeutics, creating Avere Therapeutics on Nasdaq under the ticker AVRX. Avere holders and PIPE investors will own 98-99% of the new company, with NextCure shareholders receiving 1-2% plus contingent value rights from legacy asset monetization. This …

NextCell Pharma aktie | NXTCL | Aktiekurs, analyser & nyheter